Skip to main content

Advertisement

SpringerLink
Log in

Unleashing the Potential of Ibrutinib-Loaded Nanoparticles for Cancer Treatment—A Comprehensive Review

  • Review
  • Published:
BioNanoScience Aims and scope Submit manuscript

Abstract

This review provides a comprehensive examination of ibrutinib (Ibr), highlighting its wide-ranging utilization in the treatment of diverse malignancies and its potential as a viable target for solid tumor therapy on account of its ability to inhibit numerous kinases, such as Bruton’s tyrosine kinase (BTK), which is an essential component of the B-cell receptor signaling pathway and the microenvironment of cancer. The attention is directed toward the most recent developments in nanotechnology and its growing impact on the transformation of cancer therapeutics. The article examines the potential of nanotechnology in advancing approaches to enhance the efficacy of cancer treatments, overcome drug resistance, and enable the development of novel immunotherapies. An in-depth investigation into novel approaches, including nanoencapsulation and nanocarrier-mediated delivery, reveals their potential contributions to improving the therapeutic results of Ibr. The review is situated within a multidisciplinary framework. It highlights the potential uses of these emerging nanotechnological approaches to address obstacles, minimize adverse effects, and counteract potential resistance associated with Ibr treatment. This highlights nanotechnology’s profound potential in precision oncology, particularly in enhancing the therapeutic environment for hematologic cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Data Availability

No datasets were generated or analysed during the current study.

References

  1. Sung, H., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A cancer Journal for Clinicians, 71(3), 209–249.

    Google Scholar 

  2. George, B., et al. (2020). Ibrutinib resistance mechanisms and treatment strategies for B-cell lymphomas. Cancers, 12(5), 1328.

    Article  Google Scholar 

  3. Wen, T., et al. (2021). Inhibitors targeting Bruton’s tyrosine kinase in cancers: Drug development advances. Leukemia, 35(2), 312–332.

    Article  Google Scholar 

  4. Koehrer, S., & Burger, J. A. (2023). Chronic lymphocytic leukemia: Disease biology. Acta Haematologica.

  5. Garg, N., et al. (2022). Bruton’s tyrosine kinase inhibitors: The next frontier of B-cell-targeted therapies for cancer, autoimmune disorders, and multiple sclerosis. Journal of Clinical Medicine, 11(20), 6139.

    Article  Google Scholar 

  6. Mishra, A. K., et al. (2022). Macrophages as a potential immunotherapeutic target in solid cancers. Vaccines, 11(1), 55.

    Article  MathSciNet  Google Scholar 

  7. Szklener, K., et al. (2022). Ibrutinib in the treatment of solid tumors: Current state of knowledge and future directions. Cells, 11(8), 1338.

    Article  Google Scholar 

  8. Zhang, S. Q., et al. (2015). Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. British Journal of Haematology, 170(4), 445–456.

    Article  Google Scholar 

  9. Bojarczuk, K., et al. (2015). B-cell receptor signaling in the pathogenesis of lymphoid malignancies. Blood Cells Molecules and Diseases, 55(3), 255–265.

    Article  Google Scholar 

  10. Khalaf, K., et al. (2021). Aspects of the tumor microenvironment involved in immune resistance and drug resistance. Frontiers in Immunology, 12, 656364.

    Article  Google Scholar 

  11. Ran, F., et al. (2022). Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib. European Journal of Medicinal Chemistry, 229, 114009.

    Article  Google Scholar 

  12. Paydas, S. (2019). Management of adverse effects/toxicity of ibrutinib. Critical Reviews in Oncology/Hematology, 136, 56–63.

    Article  Google Scholar 

  13. Mittal, D., Niveria, K., & Verma, A. K. (2022). Nanotechnology-based targeted delivery systems for protein kinase inhibitors in cancer therapy. Protein kinase inhibitors (pp. 779-Elsevier). 747.

    Google Scholar 

  14. Pourmadadi, M., et al. (2023). Novel epirubicin-loaded nanoformulations: Advancements in polymeric nanocarriers for efficient targeted cellular and subcellular anticancer drug delivery. Inorganic Chemistry Communications, 110999.

  15. Fathi-Karkan, S., et al. (2023). Recent advancements in the targeted delivery of etoposide nanomedicine for cancer therapy: A comprehensive review. European Journal of Medicinal Chemistry, 115676.

  16. Egbuna, C., Găman, M. A., & Jeevanandam, J. (2022). Applications of nanotechnology in drug discovery and delivery. Elsevier.

  17. Smidova, V., et al. (2021). Nanomedicine of tyrosine kinase inhibitors. Theranostics, 11(4), 1546.

    Article  Google Scholar 

  18. Li, J., et al. (2023). Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies. Journal of Hematology & Oncology, 16(1), 1–26.

    Article  MathSciNet  Google Scholar 

  19. Tshweu, L., et al. (2013). Nanoencapsulation of water-soluble drug, lamivudine, using a double emulsion spray-drying technique for improving HIV treatment. Journal of Nanoparticle Research, 15, 1–11.

    Article  Google Scholar 

  20. Alimardani, V., et al. (2023). Nanotechnology-based cell-mediated delivery systems for cancer therapy and diagnosis. Drug Delivery and Translational Research, 13(1), 189–221.

    Article  Google Scholar 

  21. Chehelgerdi, M., et al. (2023). Progressing nanotechnology to improve targeted cancer treatment: Overcoming hurdles in its clinical implementation. Molecular Cancer, 22(1), 169.

    Article  Google Scholar 

  22. Mehta, M., et al. (2023). Lipid-based nanoparticles for drug/gene delivery: An overview of the production techniques and difficulties encountered in their industrial development. ACS Materials Au.

  23. Blenke, E. O., et al. (2023). The storage and in-use stability of mRNA vaccines and therapeutics: Not a cold case. Journal of Pharmaceutical Sciences, 112(2), 386–403.

    Article  Google Scholar 

  24. Sun, D., & Lu, Z. R. (2023). Structure and function of cationic and ionizable lipids for nucleic acid delivery. Pharmaceutical Research, 40(1), 27–46.

    Article  Google Scholar 

  25. Zoulikha, M., & He, W. (2022). Targeted drug delivery for chronic lymphocytic leukemia. Pharmaceutical Research, 39(3), 441–461.

    Article  Google Scholar 

  26. Jain, H., et al. (2022). Topical delivery of Bruton’s tyrosine kinase inhibitor and curcumin-loaded nanostructured lipid carrier gel: Repurposing strategy for the psoriasis management. Pharmaceutical Development and Technology, 27(9), 975–988.

    Article  Google Scholar 

  27. Ashar, F., et al. (2022). Preparation and optimization of ibrutinib-loaded nanoliposomes using response surface methodology. Polymers, 14(18), 3886.

    Article  Google Scholar 

  28. Ponnaganti, M., & Babu, A. K. (2021). Preparation, characterization and evaluation of chitosan nanobubbles for the targeted delivery of ibrutinib. Nveo-Natural Volatiles & Essential Oils Journal| Nveo, 5017–5037.

  29. Qiu, Q., et al. (2018). Novel self-assembled ibrutinib-phospholipid complex for potently peroral delivery of poorly soluble drugs with pH-dependent solubility. An Official Journal of the American Association of Pharmaceutical Scientists, 19, 3571–3583.

    Google Scholar 

  30. Rangaraj, N., et al. (2020). QbD aided development of ibrutinib-loaded nanostructured lipid carriers aimed for lymphatic targeting: Evaluation using chylomicron flow blocking approach. Drug Delivery and Translational Research, 10, 1476–1494.

    Article  Google Scholar 

  31. Vijetha, K. A., & Reddy, M. S. Design and optimization by response surface methodology and lymphatic uptake study of lipid-based drug delivery systems of ibrutinib.

  32. Kumari, A., Yadav, S. K., & Yadav, S. C. (2010). Biodegradable polymeric nanoparticles based drug delivery systems. Colloids and Surfaces B: Biointerfaces, 75(1), 1–18.

    Article  Google Scholar 

  33. Song, P., et al. (2022). Preparation and evaluation of ibrutinib lipid-based formulations. Journal of Drug Delivery Science and Technology, 77, 103912.

    Article  Google Scholar 

  34. Vilar, G., Tulla-Puche, J., & Albericio, F. (2012). Polymers and drug delivery systems. Current drug Delivery, 9(4), 367–394.

    Article  Google Scholar 

  35. Khalid, M., & El-Sawy, H. S. (2017). Polymeric nanoparticles: Promising platform for drug delivery. International Journal of Pharmaceutics, 528(1–2), 675–691.

    Google Scholar 

  36. Raju, G. S. R., et al. (2022). Nanoparticles mediated tumor microenvironment modulation: Current advances and applications. Journal of Nanobiotechnology, 20(1), 274.

    Article  Google Scholar 

  37. Tiwari, J. N., Tiwari, R. N., & Kim, K. S. (2012). Zero-dimensional, one-dimensional, two-dimensional and three-dimensional nanostructured materials for advanced electrochemical energy devices. Progress in Materials Science, 57(4), 724–803.

    Article  Google Scholar 

  38. Fatima, F., & Anwer, M. K. (2023). Development and characterization of ibrutinib-loaded ethylcellulose-based nanosponges: Cytotoxicity assay against MCF-7 cell lines. Applied Sciences, 13(8), 4984.

    Article  Google Scholar 

  39. Alshetaili, A. S., et al. (2019). Enhanced oral bioavailability of ibrutinib encapsulated poly (lactic-co-glycolic acid) nanoparticles: Pharmacokinetic evaluation in rats. Current Pharmaceutical Analysis, 15(6), 661–668.

    Article  Google Scholar 

  40. Patel, M., et al. (2023). Core shell lipid-polymer hybrid nanoparticles for oral bioavailability enhancement of ibrutinib via lymphatic uptake. An Official Journal of the American Association of Pharmaceutical Scientists, 24(6), 142.

    Google Scholar 

  41. Murugesan, R., et al. (2021). Ibrutinib conjugated surface-functionalized multiwalled carbon nanotubes and its biopolymer composites for targeting prostate carcinoma. Journal of Materials Science, 56, 18684–18696.

    Article  Google Scholar 

  42. Armutcu, C. (2022). The investigation of parameters affecting Ibrutinib release from chitosan/tripolyphosphate/carbon nanofiber composite microspheres. Turkish Journal of Chemistry, 46(5), 1632–1641.

    Article  Google Scholar 

  43. Shakeel, F., Iqbal, M., & Ezzeldin, E. (2016). Bioavailability enhancement and pharmacokinetic profile of an anticancer drug ibrutinib by self-nanoemulsifying drug delivery system. Journal of Pharmacy and Pharmacology, 68(6), 772–780.

    Article  Google Scholar 

  44. Zhao, L., et al. (2020). Chitosan/sulfobutylether-β-cyclodextrin nanoparticles for ibrutinib delivery: A potential nanoformulation of novel kinase inhibitor. Journal of Pharmaceutical Sciences, 109(2), 1136–1144.

    Article  Google Scholar 

  45. Fuster, M. G., et al. (2023). Folic acid-modified ibrutinib-loaded silk fibroin nanoparticles for cancer cell therapy with over-expressed folate receptor. Pharmaceutics, 15(4), 1186.

    Article  Google Scholar 

  46. Li, C., et al. (2021). Sialic acid conjugate-modified liposomal platform modulates immunosuppressive tumor microenvironment in multiple ways for improved immune checkpoint blockade therapy. Journal of Controlled Release, 337, 393–406.

    Article  Google Scholar 

  47. Dhiman, S., Kaur, A., & Sharma, M. (2022). Fullerenes for anticancer drug targeting: Teaching an old dog a new trick. Mini Reviews in Medicinal Chemistry, 22(22), 2864–2880.

    Article  Google Scholar 

  48. Saliev, T. (2019). The advances in biomedical applications of carbon nanotubes. C, 5(2), 29.

    Google Scholar 

  49. Singh, J., et al. (2023). Carbon nanostructures as therapeutic cargoes: Recent developments and challenges. C, 9(1), 3.

    Google Scholar 

  50. Jha, R., et al. (2020). Smart carbon nanotubes for drug delivery system: A comprehensive study. Journal of Drug Delivery Science and Technology, 58, 101811.

    Article  Google Scholar 

  51. de Vries, R., et al. (2016). Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults. British Journal of Clinical Pharmacology, 81(2), 235–245.

    Article  Google Scholar 

  52. Lee, C. S., Rattu, M. A., & Kim, S. S. (2016). A review of a novel, Bruton’s tyrosine kinase inhibitor, ibrutinib. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners, 22(1), 92–104.

    Article  Google Scholar 

  53. Zhang, Y., et al. (2020). Applications of hyperspectral imaging in the detection and diagnosis of solid tumors. Translational Cancer Research, 9(2), 1265.

    Article  Google Scholar 

  54. Yadav, H. K. S., & Raizaday, A. (2016). Inorganic nanobiomaterials for medical imaging, in Nanobiomaterials in medical imaging (pp. 365–401). Elsevier.

  55. Davodabadi, F., et al. (2023). Aptamer-functionalized quantum dots as theranostic nanotools against cancer and bacterial infections: A comprehensive overview of recent trends. Biotechnology Progress, 39(5), e3366.

    Article  Google Scholar 

  56. Yaqoob, S. B., et al. (2020). Gold, silver, and palladium nanoparticles: A chemical tool for biomedical applications. Frontiers in Chemistry, 8, 376.

    Article  Google Scholar 

  57. Mahmoodi Chalbatani, G. (2019). Small interfering RNAs (siRNAs) in cancer therapy: A nano-based approach. International Journal of Nanomedicine, 3111–3128.

  58. Dasari, G. K., Sunkara, S., & Gadupudi, P. C. R. (2020). One-step synthesis of magnetically recyclable palladium loaded magnesium ferrite nanoparticles: Application in synthesis of anticancer drug PCI-32765. Inorganic and Nano-Metal Chemistry, 50(9), 753–763.

    Article  Google Scholar 

  59. Sánchez-Coronilla, A., et al. (2020). Theoretical study on the interactions between ibrutinib and gold nanoparticles for being used as drug delivery in the chronic lymphocytic leukemia. Journal of Molecular Liquids, 316, 113878.

    Article  Google Scholar 

  60. Yang, Z., et al. (2015). Drug and gene co-delivery systems for cancer treatment. Biomaterials Science, 3(7), 1035–1049.

    Article  Google Scholar 

  61. Indoria, S., Singh, V., & Hsieh, M. F. (2020). Recent advances in theranostic polymeric nanoparticles for cancer treatment: A review. International Journal of Pharmaceutics, 582, 119314.

    Article  Google Scholar 

  62. Gupta, N., et al. (2019). Nanomaterials-based siRNA delivery: Routes of administration, hurdles and role of nanocarriers. Nanotechnology in modern animal biotechnology: Recent trends and future perspectives, 67–114.

  63. Bor, G., Mat Azmi, I. D., & Yaghmur, A. (2019). Nanomedicines for cancer therapy: Current status, challenges and future prospects. Therapeutic Delivery, 10(2), 113–132.

    Article  Google Scholar 

  64. Teo, P. Y., et al. (2016). Co-delivery of drugs and plasmid DNA for cancer therapy. Advanced drug Delivery Reviews, 98, 41–63.

    Article  Google Scholar 

  65. Yang, Z., et al. (2023). Co-delivery of ibrutinib and hydroxychloroquine by albumin nanoparticles for enhanced chemotherapy of glioma. International Journal of Pharmaceutics, 630, 122436.

    Article  Google Scholar 

  66. Kuo, H. P., et al. (2017). Combination of ibrutinib and ABT-199 in diffuse large B-cell lymphoma and follicular lymphoma. Molecular Cancer Therapeutics, 16(7), 1246–1256.

    Article  Google Scholar 

Download references

Funding

Not applicable.

Author information

Authors and Affiliations

  1. Department of Radiology, Zabol University of Medical Science, Zabol, Iran

    Razieh Behzadmehr

  2. Natural Products and Medicinal Plants Research Center, North Khorasan University of Medical Sciences, Bojnurd, 94531-55166, Iran

    Sonia Fathi-karkan

  3. Department of Advanced Sciences and Technologies in Medicine, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, 9414974877, Iran

    Sonia Fathi-karkan

  4. School of Pharmacy, University of Management and Technology, Lahore SPH, Punjab, Pakistan

    Sobia Razzaq

  5. Department of Chemistry and Biochemistry, University of Delaware, Newark, USA

    Zeinab Moafian

  6. Department of Physics, Faculty of Sciences, University of Zabol, Zabol, 538-98615, Iran

    Abbas Rahdar

  7. Centre for Herbal Pharmacology and Environmental Sustainability, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam, 603103, Tamil Nadu, India

    Suresh Ghotekar

Authors
  1. Razieh Behzadmehr
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sonia Fathi-karkan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sobia Razzaq
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zeinab Moafian
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Abbas Rahdar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Suresh Ghotekar
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

R.B. and S.F-K. conceptualized and designed the study. S.R. and Z.M. contributed in the writing, review, and editing of the manuscript. A.R. and S.G. experimented and gathered data and prepared the text, figures, and table. The manuscript was reviewed and approved for submission by all authors.

Corresponding authors

Correspondence to Sonia Fathi-karkan, Abbas Rahdar or Suresh Ghotekar.

Ethics declarations

Ethical Approval

Not applicable.

Conflict of Interest

The authors declare no competing interests.

Research Involving Humans and Animals Statement

None.

Informed Consent

None.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Behzadmehr, R., Fathi-karkan, S., Razzaq, S. et al. Unleashing the Potential of Ibrutinib-Loaded Nanoparticles for Cancer Treatment—A Comprehensive Review. BioNanoSci. (2024). https://doi.org/10.1007/s12668-024-01445-6

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12668-024-01445-6

Keywords

Search

Navigation